02380 408 600 Contact us
Menu
×

Publications

  • Publication Subject

  • Filter by Author

Adverse drug reaction reporting in the UK: A retrospective observational comparison of Yellow Card Reports submitted by patients and healthcare professionals

  • Author

    David J McLernon Christine M Bond Philip C Hannaford Margaret C Watson Amanda J Lee Lorna Hazell Anthony Avery

    David McLernon, Christine Bond, Philip Hannaford, Margaret Watson, Amanda Lee, Lorna Hazell, Anthony Avery

  • Cite

    Drug Safety. 2010 Sep 1;33(9):775-88

View Publication

Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England

  • Author

    Vicki Osborne Deborah Layton Michael Perrio Lynda Wilton Saad A W Shakir

    Vicki Osborne, Deborah Layton, Michael Perrio, Lynda Wilton, Saad Shakir

  • Cite

    Drug Safety. 2010 Jul 1;33(7):579-91

View Publication

Safety profile of oxcarbazepine: results from a prescription-event monitoring study

  • Author

    Yvonne Buggy Deborah Layton Carole Fogg Saad A W Shakir

    Yvonne Buggy, Deborah Layton, Carole Fogg, Saad Shakir

  • Cite

    Epilepsia. 2010 May;51(5):818-29

View Publication

Drug Utilization of Intrinsa (Testosterone Patch) In England: Interim analysis of a Prescription-Event Monitoring Study to support Risk Management

  • Author

    Vicki Osborne Lorna Hazell Deborah Layton Saad A W Shakir

    Vicki Osborne, Lorna Hazell, Deborah Layton, Saad Shakir

  • Cite

    Drug Saf. 2010 Mar 1;33(3):213-21

View Publication

Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality Cornelius

  • Author

    V R Cornelius M J Perrio S A W Shakir L A Smith

    Victoria Cornelius, Michael Perrio, Saad Shakir, Leslie Smith

  • Cite

    Pharmacoepidemiol Drug Saf. 2009 Dec;18(12)

View Publication

Strontium ranelate as a cause of acute renal failure and dress syndrome

  • Author

    Deepa Iyer Yvonne Buggy Katherine O-Reilly Martin Searle

    Deepa Iyer, Yvonne Buggy, Katherine O-Reilly, Martin Searle

  • Cite

    Nephrology (Carlton). 2009 Sep;14(6):624

View Publication

The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.

  • Author

    Lorna Hazell Victoria Cornelius Lynda V Wilton Saad A W Shakir

    Lorna Hazell, Victoria Cornelius, Lynda Wilton, Saad Shakir

  • Cite

    BJU Int. 2009 Feb;103(4):506-14

View Publication

Pattern of drug utilisation for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy

  • Author

    Alexander N O Dodoo Carole Fogg Alex Asiimwe Edmund T Nartey Augustina Kodua Ofori Tenkorang David Ofori-Adjei

    Alexander Dodoo, Carole Fogg, Alex Asiimwe, Edmund Nartey, Augustina Kodua, Ofori Tenkorang, David Ofori-Adjei

  • Cite

    Malar J. 2009 Jan 5;8:2

View Publication

Safety Profile of Varenicline as used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study

  • Author

    Rachna Kasliwal Lynda V Wilton Saad A W Shakir

    Rachna Kasliwal, Lynda Wilton, Saad Shakir

  • Cite

    Drug Safety. 2009;32(6):499-507

View Publication

Hypoglycaemia with anti-diabetic drugs: Results from Prescription-Event Monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide

  • Author

    Veronika Vlckova Victoria Cornelius Rachna Kasliwal Lynda Wilton Saad A W Shakir

    Veronika Vlckova, Victoria Cornelius, Rachna Kasliwal, Lynda Wilton, Saad Shakir

  • Cite

    Drug Safety. 2009;32(5):409-18

View Publication

Risk management and outcomes of adverse events to Pioglitazone in Primary Care in the UK; an observational study

  • Author

    Carole Fogg Rachna Kasliwal Saad A W Shakir

    Carole Fogg, Rachna Kasliwal, Saad Shakir

  • Cite

    Drug Safety. 2009;32(3):229-37

View Publication

Neuraminidase inhibitors: widespread use for influenza may reveal more adverse effects

  • Author

    Layton D Cox A

    Debabrata Roy, Anthony Cox

  • Cite

    The Pharmaceutical Journal. January 2009

View Publication

Use and risk management of Carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study

  • Author

    Beate Aurich-Barrera Lynda V Wilton Saad A W Shakir

    Beate Aurich-Barrera, Lynda Wilton, Saad Shakir

  • Cite

    Drug Safety. 2009;32(1):43-54.

View Publication

Antipsychotics and stroke: the story to date

  • Author

    Layton D Cox A

    Debabrata Roy, Anthony Cox

  • Cite

    The Pharmaceutical Journal. January 2009

View Publication

Prescriber adoption of newly approved selective COX-2 inhibitors.

  • Author

    Deborah Layton Patrick C Souverein Eibert R Heerdink Saad A W Shakir A G C Egberts

    Deborah Layton, Patrick Souverein, Eibert Heerdink, Saad Shakir, Antoine Egberts

  • Cite

    Pharmacoepidemiol Drug Safety. 2008 Dec;17(12):1168-74

View Publication

Adverse drug reactions: Neuropsychiatric drug reactions associated with varenicline (Champix).

  • Author

    Layton D

    Deborah Layton

  • Cite

    The Pharmaceutical Journal. June 2008

View Publication

Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.

  • Author

    Andrew J P Cooper Sally Lettis Charlotte L Chapman Stephen J W Evans Patrick C Waller Saad Shakir Nassrin Payvandi Alison B Murray

    Andrew Cooper, Sally Lettis, Charlotte Chapman, Stephen Evans, Patrick Waller, Saad Shakir, Nassrin Payvandi, Alison Murray

  • Cite

    Pharmacoepidemiol Drug Saf. 2008 May;17(5):445-54

View Publication

Prescription Event Monitoring in the United Kingdom

  • Author

    Shakir SAW

    Saad Shakir

  • Cite

    Pharmacoepidemiology and Therapeutic Risk Management. April 2008

View Publication

European commission consultation on pharmacovigilance

  • Author

    Patrick Waller Keith Beard Toine Egberts Stephen Evans Jesper Hallas Joerg Hasford Joan-Ramon Laporte Nicholas Moore Saad Shakir Miriam Sturkenboom

    Patrick Waller, Keith Beard, Toine Egberts, Stephen Evans, Jesper Hallas, Joerg Hasford, Joan-Ramon Laporte, Nicholas Moore, Saad Shakir, Miriam Sturkenboom

  • Cite

    Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):108-9

View Publication

Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.

  • Author

    Rachna Kasliwal Lynda V Wilton Saad A W Shakir

    Rachna Kasliwal, Lynda Wilton, Saad Shakir

  • Cite

    Drug Safety. 2008;31(10):839-50

View Publication

Safety profile of esomeprazole : results of a prescription-event monitoring study of 11 595 patients in England.

  • Author

    Miranda Davies Lynda V Wilton Saad A W Shakir

    Miranda Davies, Lynda Wilton, Saad Shakir

  • Cite

    Drug Safety. 2008;31(4):313-23

View Publication

Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.

  • Author

    Deborah Layton Patrick C Souverein Eibert R Heerdink Saad A W Shakir Antoine C G Egberts

    Deborah Layton, Patrick Souverein, Eibert Heerdink, Saad Shakir, Antoine Egberts

  • Cite

    Drug Saf. 2008;31(2):143-58

View Publication

Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.

  • Author

    B Twaites L V Wilton D Layton S A W Shakir

    Beverley Twaites, Lynda Wilton, Deborah Layton, Saad Shakir

  • Cite

    Acta Diabetol. 2007 Dec;44(4):233-9

View Publication

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

  • Author

    Michael J Perrio Lynda V Wilton Saad A W Shakir

    Michael Perrio, Lynda Wilton, Saad Shakir

  • Cite

    Obesity. 2007 Nov;15(11):2712-22

View Publication

A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.

  • Author

    Michael J Perrio Lynda V Wilton Saad A W Shakir

    Michael Perrio, Lynda Wilton, Saad Shakir

  • Cite

    Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):969-78

View Publication